Cardiff Oncology Is Maintained at Overweight by Piper Sandler
Cardiff Oncology Analyst Ratings
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $10
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Cardiff Oncology (CRDF) Gets a Buy From Craig-Hallum
Cardiff Oncology Is Maintained at Buy by HC Wainwright & Co.
Cardiff Oncology Analyst Ratings
H.C. Wainwright Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Cuts Target Price to $13
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Cardiff Oncology (CRDF)
Craig-Hallum Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $8
Cardiff Oncology Analyst Ratings
Craig-Hallum Initiates Cardiff Oncology(CRDF.US) With Buy Rating, Announces Target Price $8
HC Wainwright & Co. : The Cardiff Oncology (CRDF.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $14.00.
Cardiff Oncology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $14 Price Target
Cardiff Oncology (CRDF) Gets a Buy From Piper Sandler
Cardiff Oncology Analyst Ratings
HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $14